Valuation: Roche Holding AG

Capitalization 288B 374B 315B 274B 510B 33,873B 527B 3,340B 1,328B 16,319B 1,402B 1,373B 56,993B P/E ratio 2026 *
18.9x
P/E ratio 2027 * 17.5x
Enterprise value 295B 384B 324B 282B 524B 34,807B 542B 3,432B 1,365B 16,769B 1,441B 1,411B 58,563B EV / Sales 2026 *
4.7x
EV / Sales 2027 * 4.42x
Free-Float
87.84%
Yield 2026 *
2.8%
Yield 2027 * 2.87%
1 day+0.46%
1 week+1.37%
Current month+3.02%
1 month+5.98%
3 months+24.63%
6 months+44.69%
Current year+10.09%
1 week 347.8
Extreme 347.8
361.8
1 month 331.2
Extreme 331.2
362.3
Current year 323.2
Extreme 323.2
362.3
1 year 231.9
Extreme 231.9
362.3
3 years 212.9
Extreme 212.9
362.3
5 years 212.9
Extreme 212.9
404.2
10 years 206.35
Extreme 206.35
404.2
Manager TitleAgeSince
Chief Executive Officer 51 15/03/2023
Director of Finance/CFO 59 06/06/2011
Chief Tech/Sci/R&D Officer 59 10/02/2025
Director TitleAgeSince
Director/Board Member 67 01/01/1996
Chairman 59 15/03/2023
Director/Board Member 73 03/03/2015
Change 5d. change 1-year change 3-years change Capi.($)
+0.46%+1.37%+21.32%+29.41% 374B
+2.27%+1.71%+18.94%+200.84% 930B
+1.53%+2.84%+57.51%+50.82% 589B
+2.99%+3.87%+17.88%+49.62% 402B
+1.15%+6.72%+25.81%+31.78% 315B
+0.69%+3.95%+27.53%+55.06% 307B
-0.06%-0.43%+39.19%+9.83% 296B
+2.01%+5.92%-44.70%-37.02% 216B
-0.10%-0.44%+24.11%+51.01% 197B
-2.56%+1.63%+46.95%+75.10% 188B
Average +0.84%+3.02%+23.45%+51.64% 381.47B
Weighted average by Cap. +1.28%+2.77%+25.89%+76.97%

Financials

2026 *2027 *
Net sales 62.89B 81.78B 68.91B 60.03B 111B 7,409B 115B 731B 291B 3,569B 307B 300B 12,466B 65.34B 84.96B 71.59B 62.37B 116B 7,697B 120B 759B 302B 3,708B 319B 312B 12,951B
Net income 14.63B 19.02B 16.03B 13.96B 25.93B 1,723B 26.82B 170B 67.58B 830B 71.34B 69.88B 2,900B 15.79B 20.53B 17.3B 15.07B 27.98B 1,860B 28.94B 183B 72.93B 896B 76.99B 75.41B 3,129B
Net Debt 7.92B 10.3B 8.68B 7.56B 14.05B 934B 14.53B 92.06B 36.61B 450B 38.64B 37.85B 1,571B 1.07B 1.4B 1.18B 1.03B 1.9B 127B 1.97B 12.48B 4.96B 60.96B 5.24B 5.13B 213B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
103,249
Date Price Change Volume
13/02/26 361.30 CHF +0.44% 249,409
12/02/26 359.70 CHF +0.81% 843,165
11/02/26 356.80 CHF +1.62% 955,777
10/02/26 351.10 CHF -0.76% 786,654
09/02/26 353.80 CHF -0.73% 879,073
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
359.70CHF
Average target price
357.45CHF
Spread / Average Target
-0.62%

Quarterly revenue - Rate of surprise